OptimizeRx Shares Tumble on Cut to Outlook, Despite 3Q Beat

By Elias SchisgallShares of OptimizeRx tumbled after the company cut its guidance, even as its third-quarter results exceeded analyst expectations.The stock was down 21% at $7.11 in after-hours trading on Wednesday. Shares closed down 4.3% at $8.95, down 27% year to date.The healthcare technology c…